Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Disease and allergy testing kit provider Omega Diagnostics said it would delay the release of its annual results until September, while warning it expected to post a loss for the period.
The company said it needed further time to 'gain clarity regarding certain ongoing commercial discussions and other post-balance sheet events'.
Pre-tax losses for the year through March were expected to be £0.2m, narrowing from a loss of £1.0m on-year.
Revenue was expected to fall to £9.8m, down from £13.6m, following the sale of the company's infectious disease assets and discontinuation of its German business.
Revenue from from continuing operations was seen rising 5% to £8.8m, while Ebitda from continuing operations was expected at £0.2m, turning around an on-year loss of £0.8m.
Trading in the first quarter of the new financial year was in line with management expectations, Omega Diagnostics said.
At 1:23pm: (LON:ODX) Omega Diagnostics Group PLC share price was -0.5p at 9p